Acquired haemophilia A: Balancing on the edge of haemostasis – Case series
Open Access
- 1 January 2025
- journal article
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 12 (1) , 82-86
Abstract
Introduction: Emicizumab has recently been investigated for prophylactic use in patients with acquired haemophilia A. While it shows promising results in effectively reducing bleeding episodes, there remains a very delicate question concerning the risk of thromboembolic events. Recently published prospective studies reported thrombotic events in 4% to 8% of cases. However, these studies excluded patients with an increased thrombotic risk or those undergoing treatment for a thromboembolic disease, situations frequently occurring in this elderly patient group. Therefore, we urge clinicians to critically assess which patients would benefit from emicizumab treatment and which would not. Case series: Here, we present a case series from a Dutch haemophilia treatment centre that highlights the complexity of patients currently managed with acquired haemophilia A. The series discusses individual patient characteristics, underlying comorbidities, and responses to initiated therapy with bypassing agents and immunosuppressive therapy. The pros and cons of emicizumab therapy in these individual patients are discussed. Discussion: We suggest considering the use of emicizumab in patients with acquired haemophilia A through a personalised approach. This approach involves assessing thrombotic risk on one hand and focusing on controlling bleeding on the other. It should account for the need to rapidly eradicate the inhibitor in cases of acute bleeding necessitating bypassing agents. Alternatively, it should consider the possibility of postponing or reducing immunosuppressive therapy in frail patients without overt bleeding, for whom emicizumab presents an ideal prophylactic option.Keywords
This publication has 12 references indexed in Scilit:
- Prognostic factors for recurrence in acquired hemophilia A-results from a long-term observational studyResearch and Practice in Thrombosis and Haemostasis, 2025
- Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 studyThe Lancet Haematology, 2023
- A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia AJournal of Thrombosis and Haemostasis, 2023
- Evaluation of the Safety of Emicizumab Prophylaxis in Persons with Hemophilia A: An Updated Summary of Thrombotic Events and Thrombotic MicroangiopathiesBlood, 2021
- Should emicizumab be used in patients with acquired hemophilia A?Journal of Thrombosis and Haemostasis, 2020
- Treatment of acquired hemophilia A, a balancing act: results from a 27‐year Dutch cohort studyAmerican Journal of Hematology, 2020
- International recommendations on the diagnosis and treatment of acquired hemophilia AHaematologica, 2020
- Bleeding and Response to Hemostatic Therapy in Acquired Hemophilia A (AHA): Results from the GTH-AH 01/2010 StudyBlood, 2020
- Emicizumab Prophylaxis in Hemophilia A with InhibitorsNew England Journal of Medicine, 2017
- Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)Journal of Thrombosis and Haemostasis, 2012